OWOlivia Wagemann

Olivia Wagemann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olivia Wagemann has a total of 123 co-authors. Here are the top co-authors by number of shared publications:

  • Johannes Levin

    Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany

    6 shared publications
  • Elisabeth Wlasich

    Department of Neurology, LMU University Hospital, LMU Medizin Ludwig‐Maximilians‐Universität München Munich Germany

    5 shared publications
  • Georg Nübling

    Department of Neurology, LMU University Hospital, LMU Medizin Ludwig‐Maximilians‐Universität München Munich Germany

    4 shared publications
  • Anna Stockbauer

    Department of Neurology, LMU University Hospital, LMU Medizin Ludwig‐Maximilians‐Universität München Munich Germany

    3 shared publications
  • Catharina Prix

    Department of Neurology University Hospital Ludwig‐Maximilians‐University (LMU) Munich Munich Germany

    3 shared publications
  • Lena Marth

    Department of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany

    3 shared publications

Latest Publications

  • Open Access

    Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome

    by Olivia Wagemann, Georg S. Nuebling, Katja Sandkühler, Elisabeth Wlasich, Sandra V. Loosli, Catharina Prix, Anna Christina Stockbauer, Lena Marth, Anabel Forte, Jonathan Vöglein, et al.

    Background and ObjectivesAdults with Down syndrome (DS) have an increased risk of developing early Alzheimer disease. While our previous cross-sectional study investigated the blood proteome in the...

  • Open Access

    Frailty in Adults With Down Syndrome: Cognitive, Functional and Biomarker Associations

    by Georg Nübling, Lena Marth, Katja Sandkühler, Anna Stockbauer, Elisabeth Wlasich, Alexander Jäck, Olivia Wagemann, Julia Kustermann, Steffen Halbgebauer, Hayrettin Tumani, et al.

    Background: Down syndrome (DS) entails widespread age‐related functional decline affecting multiple organ systems, including genetically determined early‐onset Alzheimer disease (DSAD), resulting in an increased vulnerability to frailty early in life. We investigated the relationship between frailty, cognition and intellectual disability (ID) in adults with DS and explored biomarkers associated with frailty. Methods: This cross‐sectional study investigated 148 consecutive patients at a DSAD outpatient clinic. We applied correlation analyses and hierarchical linear models to determine associations of the Frailty Index for people with Intellectual Disabilities—short form (ID‐FI SF ) with measures of cognition (Cambridge cognitive assessment, CAMCOG‐DS), adaptive function (short adaptive behaviour scale, SABS), motor function (SPES/SCOPA), a screening tool (dementia screening questionnaire in individuals with intellectual disabilities, DSQIID‐G) for dementia‐related change in ADL (activities of daily living) performance, and ID severity (DSM‐5). Patients were stratified as cognitively healthy, DS‐MCI, DSAD dementia, secondary cognitive decline (CD) or CD of unknown cause. Exploratory analyses included blood biomarkers, bioimpedance measurements and indirect calorimetry. Results: Both baseline ID severity ( β = 0.093, p = 0.014) and cognitive performance (CAMCOG‐DS, β = −0.0033, p < 0.001) were independently associated with ID‐FI SF scores. Acquired cognitive decline was associated with (pre)frailty irrespective of aetiology. After adjustment for ID severity and cognition, ID‐FI SF scores were associated with adaptive function (SABS: β = −0.0033, p < 0.001), motor function (SPES‐SCOPA: β = 0.015, p < 0.001), change in ADL performance (DSQIID‐G: β = 0.0061, p < 0.001) and medication burden ( β = 0.016, p < 0.001). Exploratory biomarker analyses identified associations with ID‐FI SF scores for markers of neurodegeneration, inflammation, body composition, cardiac function and cellular stress signalling. Conclusions: Frailty in DS is associated with both ID severity and acquired cognitive decline. Future studies should determine whether severe baseline ID increases susceptibility to frailty or primarily influences frailty measurement through lower baseline functional abilities, potentially necessitating ID‐adapted frailty thresholds. Biomarker associations further support a multifactorial model of frailty involving neurodegeneration, inflammation and sarcopenia‐related processes.

  • Open Access

    Combining blood biomarkers and the German version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID‐G) for diagnosing cognitive decline in Down syndrome

    by Olivia Wagemann, Charlotte Götz, Elisabeth Wlasich, Katja Sandkühler, Catharina Prix, Anna Stockbauer, Lena Marth, Alexander Jäck, Steffen Halbgebauer, Hayrettin Tumani, et al.

    INTRODUCTION: Individuals with Down syndrome (DS) are at risk for Alzheimer's disease (AD). However, diagnosis remains challenging due to variability of intellectual ability and symptom presentation. To investigate whether serum AD biomarkers enhance accuracy of the German version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID‐G), we combined test scores with neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels. METHODS: Seventy‐eight DS individuals (49% female) completed the DSQIID‐G; previous cohort data were added for a pooled sample ( n = 164, 47% female). Serum NfL and GFAP were assessed using the automated microfluid Ella system. RESULTS: Combining the DSQIID‐G with NfL or GFAP resulted in improved accuracy in every diagnostic subgroup. The Youden index in the pooled samples yielded a cut‐off score at 6.5. DISCUSSION: The DSQIID‐G is a robust screening tool and its combination with AD blood biomarkers aids earlier identification of individuals requiring further diagnostics for DS‐associated AD.


  • Open Access

    Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia

    by Lena Marth, Francisco J. Martinez-Murcia, Juan-Manuel Górriz-Sáez, Jannis Denecke, Michael Ewers, Catharina Prix, Anna Christina Stockbauer, Alexander Maximilian Bernhardt, Olivia Wagemann, Elisabeth Wlasich, et al.

    Behavioral and neuropsychiatric symptoms are common in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). However, little is known about their patterns, time course, and association with brain atrophy. We, therefore, aimed to describe behavioral and neuropsychiatric phenotypes in patients with FTD and PPA, leveraging a hypothesis-free/data-driven approach. We included participants diagnosed with behavioral variant FTD (bvFTD) or PPA according to Rascovsky and Gorno-Tempini criteria from the German Center for Neurodegenerative Diseases Clinical Registry Study of Neurodegenerative Diseases-FTD prospective multicenter observational cohort study. Symptoms were assessed using the Neuropsychiatric Inventory-Questionnaire. Principal component analysis (PCA) was used to delineate symptom groups. Subsequently, frequency and severity across diagnostic groups were examined. We applied linear mixed-effects models to describe the longitudinal evolution of symptoms. Associations with MRI-assessed atrophy were investigated using linear regression models. A total of 314 patients (42.4% female, mean age 65.52 [SD 9.0] years) with bvFTD or PPA were included. MRI was available for 134 of 314 individuals. PCA revealed 4 natural symptom groups, labeled active behavioral, passive behavioral, affective, and psychotic phenotypes. Symptom groups were observed at comparable frequencies across diagnostic groups. Time from symptom onset (0.130 [0.044-0.217], p < 0.003), sex (1.376 [0.666-2.087], p < 0.001), and the interaction between the nonfluent variant of PPA and sex (-1.940 [-3.242 to -0.638], p = 0.004) showed a significant effect on the active behavioral phenotype, with symptom severity increasing over time and being most pronounced in men with bvFTD. Patients with bvFTD exhibited more severe passive behavioral symptoms compared with any other diagnostic group. For the affective phenotype, a significant interaction between time and sex (0.063 [0.010-0.117], p = 0.021) indicated a progressive increase in symptom severity in men over time. Furthermore, we found robust neuroanatomical correlations of passive behavioral symptoms with subcortical and bilateral frontal and cingulate cortical atrophy. Our findings demonstrate that behavioral and neuropsychiatric symptoms are prevalent in both bvFTD and PPA. Their severity depends on the disease duration, phenotypic group, and sex. This detailed understanding of symptomatology is crucial for optimizing patient care, diagnostic evaluations, and the design of clinical trials. Limitations comprise the lack of neuropathologic validation and the limited availability of MRI data.


  • Open Access

    Ein Review und Leitfaden für die adäquate und interdisziplinäre (sozial-)medizinische Versorgung von Menschen mit einem Down-Syndrom und einer dementiellen Entwicklung

    by Olivia Wagemann, Valentina A. Tesky, Arthur Schall, Georg Nübling, Elisabeth Wlasich, Theresa Hüer, Anke Walendzik, Milena Weitzel, Godwin D. Giebel, Pascal Raszke, et al.

    Zusammenfassung: Die Alzheimer-Krankheit (AD) zählt zu den häufigsten neurodegenerativen Erkrankungen im Alter. Menschen mit Down-Syndrom (DS) haben aufgrund der Trisomie 21 und der Überexpression des Amyloid Precursor Protein ein deutlich erhöhtes Risiko für eine Demenz durch AD mit Prävalenzen von bis zu 88% jenseits des 65. Lebensjahres. Dennoch fehlen strukturierte Leitlinien zur Diagnostik und Therapie der Down-Syndrom-assoziierten Alzheimer-Demenz (DSAD). Es wurde eine narrative Übersicht der relevanten Literatur zu Ätiologie, Diagnostik, Therapie und Versorgung bei DSAD erstellt. Zudem erfolgte eine Evaluation bestehender Standards der allgemeinen Demenzdiagnostik bzgl. der Besonderheiten bei Menschen mit DS. Etablierte diagnostische Verfahren sind auch bei Menschen mit DS anwendbar, müssen jedoch hinsichtlich Symptomwahrnehmung, Testdurchführung und Befundinterpretation angepasst werden. Die Sensibilisierung von Angehörigen und Versorgern sowie die frühzeitige Anbindung an spezialisierte Zentren sind entscheidend für eine zielgerichtete Diagnostik und Therapie. Eine verbesserte Versorgung von Menschen mit DSAD erfordert eine enge Kooperation zwischen Regelversorgung und spezialisierten Einrichtungen. Dieses Review gibt einen Überblick über die medizinischen, diagnostischen und strukturellen Anforderungen bei Verdacht auf DSAD und leitet praxisnahe Handlungsempfehlungen für die Versorgung ab. Der abschließende Leitfaden soll somit helfen, bestehende Unsicherheiten in der Praxis zu reduzieren und eine langfristige, bedarfsgerechte Versorgung sicherzustellen.


  • Open Access

    Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease

    by Olivia Wagemann, Georg Nübling, Francisco Jesús Martínez‐Murcia, Elisabeth Wlasich, Sandra V. Loosli, Katja Sandkühler, Anna Stockbauer, Catharina Prix, Sabrina Katzdobler, Agnese Petrera, et al.

    INTRODUCTION: Adults with Down syndrome (DS) show increased risk for Alzheimer's disease (AD) due to the triplication of chromosome 21 encoding the amyloid precursor protein gene. Further, this triplication possibly contributes to dysregulation of the immune system, furthering AD pathophysiology.METHODS: Using Olink Explore 3072, we measured ∼3000 proteins in plasma from 73 adults with DS and 15 euploid, healthy controls (HC). Analyses for differentially expressed proteins (DEP) were carried out, and pathway and protein network enrichment using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG), and STRING database was investigated. Within DS, the LASSO (least absolute shrinkage and selection operator) feature selection was applied.RESULTS: We identified 253 DEP between DS and HC and 142 DEP between symptomatic and asymptomatic DS. Several pathways regarding inflammatory and neurodevelopmental processes were dysregulated in both analyses. LASSO feature selection within DS returned 15 proteins as potential blood markers.DISCUSSION: This exploratory proteomic analysis found potential new blood biomarkers for diagnosing DS‐AD in need of further investigation.Highlights: Inflammatory pathways are dysregulated in symptomatic versus asymptomatic DS. NFL and GFAP are confirmed as powerful biomarkers in DS with clinical and/or cognitive decline. Further circulating proteins were identified as potential blood biomarkers for symptomatic DS.


  • Differenzialdiagnosen bei demenzieller Entwicklung

    by Olivia Wagemann, Adrian Danek

    Im klinischen Alltag sind Demenzkrankheiten von anderen Storungen der Kognition, des Sozialverhaltens und der emotionalen Kontrolle abzugrenzen. Durch eine dezidierte Stufendiagnostik mussen reversible Ursachen mit zugigem Handlungsbedarf von langsam progredienten Prozessen unterschieden werden. Abstract In clinical practice, dementia must be distinguished from other disorders of cognition, social behavior, and emotional control. A dedicated stepwise diagnosis must differentiate reversible causes with urgent need for action from slowly progressive processes.

  • Open Access

    Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network

    by Olivia Wagemann, Yan Li, Jason Hassenstab, Andrew J. Aschenbrenner, Nicole S. McKay, Brian A. Gordon, Tammie L. S. Benzinger, Chengjie Xiong, Carlos Cruchaga, Alan E. Renton, et al.

    INTRODUCTION: Studies suggest distinct differences in the development, presentation, progression, and response to treatment of Alzheimer's disease (AD) between females and males. We investigated sex differences in cognition, neuroimaging, and fluid biomarkers in dominantly inherited AD (DIAD).METHODS: Three hundred twenty‐five mutation carriers (55% female) and one hundred eighty‐six non‐carriers (58% female) of the Dominantly Inherited Alzheimer Network Observational Study were analyzed. Linear mixed models and Spearman's correlation explored cross‐sectional sex differences in cognition, cerebrospinal fluid (CSF) biomarkers, Pittsburgh compound B positron emission tomography (11C‐PiB PET) and structural magnetic resonance imaging (MRI).RESULTS: Female carriers performed better than males on delayed recall and processing speed despite similar hippocampal volumes. As the disease progressed, symptomatic females revealed higher increases in MRI markers of neurodegeneration and memory impairment. PiB PET and established CSF AD markers revealed no sex differences.DISCUSSION: Our findings suggest an initial cognitive reserve in female carriers followed by a pronounced increase in neurodegeneration coupled with worse performance on delayed recall at later stages of DIAD.


  • Regression bei jungen Erwachsenen mit einem Down-Syndrom: Eine Fallserie

    by Olivia Wagemann, Sandra V. Loosli, Jonathan Vöglein, Catharina Prix, Elisabeth Wlasich, Georg Nübling, Adrian Danek, Johannes Levin

    Zusammenfassung: Hintergrund In Abgrenzung zur Depression und zur früh beginnenden Alzheimer-Demenz ist bei jungen Erwachsenen mit einem Down-Syndrom ein Regressions-Syndrom im Sinne eines plötzlich auftretenden, weitgehend irreversiblen Verlusts erlernter Fähigkeiten sowie Verhaltensänderungen beschrieben. Die vorliegende Fallserie verdeutlicht die heterogene Präsentation, die Herausforderungen im differentialdiagnostischen und therapeutischen Vorgehen sowie prognostische Konsequenzen des Syndroms. Methodik Es erfolgte eine Evaluation anhand der CAMDEX-DS (Cambridge Examination for Mental Disorders of Older People with Down Syndrome and Others with Intellectual Disabilities) sowie des Diagnosekatalogs der DSMIG-USA (Down-Syndrome Medical Interest Group USA). Ergebnisse Für alle drei Patienten ließ sich mittels DSMIG-USA-Kriterien und nach Ausschluss somatischer oder psychiatrischer Ursachen ein mindestens wahrscheinliches Regressions-Syndrom feststellen. Diskussion Die ausführliche differentialdiagnostische Abklärung einer unklaren Regression bei jungen Menschen mit einem Down-Syndrom erlaubt bei entsprechender Verdachtsdiagnose eine rasche Einleitung therapeutischer und sozialmedizinischer Maßnahmen. Der Diagnosekatalog der DSMIG-USA erleichtert dabei die Einordnung der diffusen und vielseitigen Symptomatik.


  • Differenzialdiagnosen bei demenzieller Entwicklung

    by Olivia Wagemann, Adrian Danek

    Im klinischen Alltag sind Demenzkrankheiten von anderen Störungen der Kognition, des Sozialverhaltens und der emotionalen Kontrolle abzugrenzen. Durch eine dezidierte Stufendiagnostik müssen reversible Ursachen mit zügigem Handlungsbedarf von langsam progredienten Prozessen unterschieden werden. Publication Date: 21 January 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany